<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02333643</url>
  </required_header>
  <id_info>
    <org_study_id>CLS003-CO-PR-002</org_study_id>
    <nct_id>NCT02333643</nct_id>
  </id_info>
  <brief_title>A Phase 2 Efficacy Study of CLS003 ICVT in Subjects With Cutaneous Warts.</brief_title>
  <official_title>A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Study to Evaluate Efficacy and Safety of Topical Ionic Contra-viral Therapy (ICVT) Comprised of CLS003 in Cutaneous Warts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cutanea Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cutanea Life Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2, randomized, vehicle-controlled, double-blind study to assess the efficacy, safety
      and pharmacodynamics (PD) of topically applied CLS003 in otherwise healthy patients with
      cutaneous warts.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in morphological wart assessment</measure>
    <time_frame>Days 14, 28, 42, 70, 98</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Wart size and morphology assessment by standardized clinical photography</measure>
    <time_frame>Days 14, 28, 42, 70, 98</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in HPV viral load assessment of target lesions by quantitative PCR</measure>
    <time_frame>Days 14, 28, 42, 70, 98</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in wart size</measure>
    <time_frame>Days 14, 28, 42, 70, 98</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the HPV viral load</measure>
    <time_frame>Days 14, 28, 42, 70, 98</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in mean HPV viral load</measure>
    <time_frame>Days 14, 28, 42, 70, 98</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent clearance of warts</measure>
    <time_frame>Days 14, 28, 42, 70, 98</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event to evaluate safety and tolerability of CLS003</measure>
    <time_frame>Days 0-98</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Cutaneous Warts</condition>
  <arm_group>
    <arm_group_label>CLS003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical digoxin/furosemide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Digoxin topical formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Furosemide topical formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle topical formulation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLS003</intervention_name>
    <arm_group_label>CLS003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <arm_group_label>Furosemide topical formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <arm_group_label>Digoxin topical formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle topical</intervention_name>
    <arm_group_label>Vehicle topical formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  absence of evidence of any active or chronic disease;

          -  Free of clinical significant systemic or dermatologic disorder, which, in the opinion
             of the investigator, will interfere with the study results or increase the risk of
             Adverse Events;

          -  Have at least 2 (non-subungual) common warts or at least 2 plantar warts on
             non-genital, nonfacial skin

        Exclusion Criteria:

          -  Any clinically significant abnormality that in the opinion of the investigator would
             interfere with the study objectives or compromise subject safety;

          -  For women: a positive pregnancy test and/or nursing at screening or women who plan to
             become pregnant or are breastfeeding;

          -  A positive test for drugs of abuse at screening;

          -  History of alcohol or illicit drug abuse (alcohol abuse defined as alcohol consumption
             &gt; 28 units/week);

          -  Positive test results for Hepatitis B, Hepatitis C or HIV;

          -  Have used salicylic acid or any other over-the-counter wart-removing product in the
             treatment area within 30 days prior to starting the study or cryotherapy within 60
             days of starting the study;

          -  Have required systemic intake of immunosuppressive or immunomodulatory medication
             (including oral or parenteral corticosteroids) within 30 days prior to enrollment or
             during the course of the study. Routine use of inhaled or intranasal corticosteroids
             during the study is allowed;

          -  Have a known sensitivity to any of the investigational product ingredients

          -  Clinically relevant abnormal laboratory results, ECG, vital signs, or physical
             findings at screening;

          -  Participation in an investigational drug or device study within 3 months prior to
             screening or more than 4 times in the past year;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. (Koos) Burggraaf, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Human Drug Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LUMC/Centre for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2014</study_first_submitted>
  <study_first_submitted_qc>January 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2015</study_first_posted>
  <disposition_first_submitted>July 25, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>July 25, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 28, 2016</disposition_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

